<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        82-171-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NORACTONE 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SPIRONOLACTONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1000
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        207.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1055]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Dallah Health Care Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C03DA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1. WHAT NORACTONE IS AND WHAT IT IS USED FOR The name of your medicine is NORACTONE. The active ingredient is Spironolactone. This belong to a group of medicines called potassium-sparing diuretics (water tablets), which help you lose excess fluid from your body. This medicine is used to: □ Congestive heart failure (a condition where your heart&rsquo;s pumping action has become weak because of too much fluid in your body.) □ Nephrotic syndrome (a kidney disorder) □ Liver cirrhosis with fluid retention (edema) and swelling of the abdomen (ascites) □ A cancerous disease with swelling of the abdomen (malignant ascites) □ Diagnosis and treatment of primary aldosteronism (a condition where excess hormone is produced).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take NORACTONE: Do not take NORACTONE tablets and tell your doctor if you: □ Are allergic (hypersensitive) to Spironolactone or any of the other ingredients in NORACTONE tablets (see section 6) □ Have diabetes with or without kidney problems □ Have Addison&rsquo;s disease (weakness, loss of energy, low blood pressure and dark pigmentation of the skin □ Have kidney problems which may be severe or worsening □ Have high blood levels of potassium □ Are not passing urine. Take special care with NORACTONE: Check with your doctor or pharmacist before taking NORACTONE tablets if you have: □ A diet high in potassium □ Low blood levels of sodium □ Liver cirrhosis □ Been passing small amounts of urine □ A severe illness □ Ever had too much acid in the body □ An inherited disorder of the red blood pigment hemoglobin causing skin blisters, abdominal pain and nervous system disorders (porphyria) □ Abnormal periods or swollen breasts. Taking other medicines: Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Especially: □ Blood pressure lowering medicines (antihypertensives) such as ACE inhibitors (e.g. captopril or enalapril) and angiotensin-II receptor antagonists (such as valsartan or losartan) □ Chlorpropamide (used in diabetes) □ Digoxin (used in some heart conditions) □ Cyclosporine or tacrolimus (used to prevent organ transplant rejection, treat rheumatoid arthritis, eczema or psoriasis) □ Fludrocortisone (a corticosteroid) □ Warfarin (used to thin the blood) □ Other potassium-sparing diuretics (water tablets) □ Lithium (used for some mental illnesses) □ Non-steroidal anti-inflammatory drugs (NSAIDs) such as indometacin and mefenamic acid □ Aspirin (to reduce pain, inflammation and high temperature) □ Potassium supplements (potassium salts) □ Noradrenalin (norepinephrine) (used for low blood pressure or heart problems) □ An anesthetic □ Carbenoxolone (an ulcer healing drug). Taking NORACTONE with food and drink: □ Swallow the tablets with water and preferably with food. Pregnancy and breastfeeding: Pregnancy If you are pregnant or planning to become pregnant, speak to your doctor before taking this medicine. Breast-feeding NORACTONE tablets should not be taken if you are breast-feeding. Driving and using machines: NORACTONE tablets may cause dizziness or drowsiness. Make sure you are not affected before you drive or operate machinery. Important information about some of the ingredients of NORACTONE: If you have been told you have intolerance to some sugars, contact your doctor before taking this medicine, as it contains a type of sugar called lactose. Interference with Tests: If you are to have liver function tests, you are to be tested for diabetes or need to have other tests related to diabetes, tell your doctor that you are taking NORACTONE tablets. NORACTONE tablets may need to be stopped at least three days before a diabetes test. Tests to be performed: Your doctor may want to carry out tests to monitor the levels of fluid and chemicals in your body, especially if you are elderly or have impaired liver or kidney function.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take NORACTONE tablets exactly as your doctor has told you. If you are not sure, check with your doctor or pharmacist. Adults: □ Congestive heart failure: 100mg a day. The maintenance dose is 25- 200mg a day. In difficult or severe cases, up to a maximum of 400mg a day may be taken. □ Nephrotic syndrome: 100-200mg a day. □ Liver cirrhosis with fluid retention and swelling of the abdomen: 100-400mg a day. Your doctor will decide on the best maintenance dose for you. □ A cancerous disease with swelling of the abdomen: 100-200mg a day. Your doctor will decide on the best maintenance dose for you. In severe cases, up to a maximum of 400mg a day may be taken. □ Primary aldosteronism diagnosis: Long test: 400mg a day for 3-4 weeks. Short test: 400mg a day for 4 days. □ Primary aldosteronism treatment: 100-400mg a day in preparation for surgery. If surgery is not to be carried out, your doctor will decide on the best maintenance dose for you. Elderly: Your doctor will decide on the best dose for you. If you have severely impaired liver or kidney function, your doctor may prescribe a different dose. Children: Usual starting dose is 3mg per kg of bodyweight a day, to be taken in divided doses. Your doctor will adjust the dose depending on the response to treatment. If necessary, the tablets may be crushed and dispersed in food or drink. If you take more NORACTONE than you should: □ If you (or someone else) swallow a lot of tablets at the same time, or you think a child may have swallowed any, contact your nearest hospital casualty department or tell your doctor immediately. □ Symptoms of an overdose include drowsiness, mental confusion, feeling or being sick, dizziness, diarrhea, decreased blood levels of sodium, increased blood levels of potassium (symptoms include &lsquo;pins and needles&rsquo; or tingling, unusual tiredness or weakness, muscular weakness, paralysis with a loss of muscle tone, muscle spasm). If you forget to take NORACTONE: If you forget to take a dose, take it as soon as you remember it and then take the next dose at the right time. Do not take a double dose to make up for a forgotten dose. If you stop taking NORACTONE: □ It is important to keep taking NORACTONE until your doctor tells you to stop, even if you start to feel better. □ If you stop taking the tablets too soon, your condition may get worse. □ If you have any further questions on the use of this medicine, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, NORACTONE tablets can cause side effects, although not everybody gets them</p><p>Stop taking NORACTONE and contact your doctor at once if you develop: □ High blood levels of potassium (muscle twitching or weakness, irregular heartbeat, unusual tiredness or weakness, paralysis with or without loss of muscle tone, circulatory failure), especially if you have impaired kidney function or a diet high in potassium. Contact your doctor immediately if you: □ Notice signs of an allergic reaction (hypersensitivity) such as swelling of the face, lips, tongue or throat, difficulty breathing or swallowing, shock, collapse, skin rash or itching. Tell your doctor or pharmacist if you notice any of the following side effects, they get worse or if you notice anything not listed: □ Blood: Increase in blood levels of nitrogen or urea especially in those with impaired kidney function, altered numbers and types of blood cells. If you notice increased bruising, nosebleeds, sore throats or infections, you should tell your doctor who may want you to have a blood test. □ Metabolism and nutrition: Low blood levels of sodium, changes in the levels of chemicals in the body. □ Nervous system: Lack of muscle control or coordination, drowsiness, dizziness, headache, clumsiness. □ Psychiatric: Tiredness. □ Liver: A poisonous effect on the liver. □ Stomach and intestines: Inflammation of the stomach lining, bleeding in the stomach, stomach or intestinal ulcers, stomach cramps, diarrhea, being sick. □ Skin: Skin rashes including pale or red irregular raised patches with severe itching (hives), hair loss, itchiness and blistering of the skin around the lips and the rest of the body (Stevens-Johnson syndrome), detachment of the top layer of skin from the lower layers of skin all over the body (toxic epidermal necrolysis), skin rash, fever and swelling (which could be symptoms of something more serious, drug rash and eosinophilia and systemic symptoms). □ Muscle and bone: Bone softening due to vitamin D deficiency. □ Kidneys: Acute kidney failure particularly in those who already have impaired kidney function. □ Reproductive system: Enlarged breasts in men, changes in voice pitch, reduced sexual potency in men, decreased sexual ability, breast tenderness and increased hair growth in females, irregular periods, sweating. Tell your doctor or pharmacist if you notice any of the above side effects, they get worse or if you notice anything not listed</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>□ Keep out of the reach and sight of children. □ Do not store above 30&deg;C, protect from humidity and light. □ Do not use NORACTONE after the expiry date which is stated on the carton and on the blister, after (EXP).Date. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What NORACTONE contains: □ The active substance is Spironolactone. Each tablet contains 25 mg of Spironolactone. □ The other ingredients are: Anhydrous Dibasic Calcium Phosphate, Lactose, Maize Starch, Sodium Lauryl Sulphate, Magnesium Stearate and Colloidal Anhydrous Silica.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                NORACTONE 25 mg Tablets are white circular flat face bevelled edge tablet plain on both sides.
□ Boxes of 30 blistered tablets of NORACTONE 25 Tablets.
□ Boxes of 1000 blistered tablets of NORACTONE 25 Tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Saudi Arabia: To report any side effect(s): National Pharmacovigilance Center (NPC): Fax: +966-11-205- 7662, SFDA Call center: 19999, E-mail: npc.drug@sfda.gov.sa, Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                june 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>نوراكتون ّ هو اسم دوائك. سبايرونولاكتون هو المكون الفعال. وهو ينتمي إلى مجموعة من الأدوية تعرف بمدرات البول الموفرة للبوتاسيوم و التي تساعدك على التخلص من السوائل الزائدة في جسمك. يستخدم هذا الدواء لعلاج: □ فشل القلب الاحتقاني (وهي الحالة التي تكون فيها عملية ضخ الدم من القلب ضعيفة بسبب كثرة تجمع السوائل في الجسم). □ المتلازمة الكلائية (اضطراب في الكلى). □ تشمع الكبد مع احتباس في السوائل (وذمة) وتورم في البطن (استسقاء). □ مرض سرطاني مع تورم في البطن (استسقاء خبيث). □ لتشخيص و علاج الألدوستيرونية الأولية (وهي الحالة المرضية التي تحدث نتيجة زيادة إفراز هرمون الألدوستيرون في الجسم).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول أقراص نوراكتون و أخبر طبيبك: □ إذا كنت تعاني من حساسية اتجاه سبايرونولاكتون أو لأي من مكونات أقراص نوراكتون (انظر القسم ٦). ً بمرض السكري مع أو بدون مشاكل في الكلى. □ إذا كنت مصابا □ إذا كنت تعاني من مرض أديسون (ضعف عام، فقدان الطاقة، انخفاض في ضغط الدم و تصبغ داكن في الجلد). □ إذا كنت تعاني من مشاكل في الكلى والتي قد تكون شديدة أو في حالة تدهور. □ إذا كان لديك ارتفاع في مستويات البوتاسيوم. □ في حالة انقطاع البول (عدم التبول). الاحتياطات عند استعمال نوراكتون: استشر طبيبك أو الصيدلاني قبل تناولك نوراكتون إذا: □ كنت تتبع نظام غذائي يحتوي على كمية عالية من البوتاسيوم في الدم. □ كنت تعاني من انخفاض في مستويات الصوديوم. □ كنت تعاني تشمع الكبد. □ كانت كمية البول التي تخرج من الجسم قليلة. □ كنت تعاني من مرض شديد (وخيم). □ إذا عانيت في أي وقت مضى من زيادة الحموضة في الجسم. □ كنت تعاني من اضطراب مورث في تكوين الصبغة المكونة للهيموغلوبين مما يسبب نفطة (بثور)، آلام في البطن واضطرابات في الجهاز العصبي (البرفيرية) □ اضطرابات في الدورة الشهرية أو تورم في الثدي تناول أدوية أخرى: ً أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها من دون وصفة الرجاء إخبار الطبيب أو الصيدلي إذا كنت تأخذ أو أخذت مؤخرا طبية، وعلى وجه الخصوص الأدوية التالية: □ الأدوية التي تسخدم لتخفيض ضغط الدم مثل: مثبطات الإنزيم المحول للأنجيوتنسين (على سبيل المثال: كابتوبريل أو إنالابريل) و مضادات مستقبلات الأنجيوتنسين ۲ (مثل فالسارتان و لوسارتان) □ كلوربروبامايد (يستخدم في مرض السكري) □ الديجوكسين (يستخدم في بعض أمراض القلب) □ سايكلوسبورين أو تاكروليمس (تستخدم هذه الأدوية لمنع رفض الجسم للعضو المزروع، لعلاج التهاب المفاصل الروماتويدي ، الأكزيما أو الصدفية) □ فلودروكورتيزون (كورتيكوستيرويد) □ الوارفارين (يستخدم لمنع تجلط الدم) □ مدرات البول الأخرى الموفرة للبوتاسيوم □ الليثيوم (لبعض أنواع الأمراض النفسية) □ مضادات الالتهاب غير الستيرويدية مثل إندوميتاسين و حمض الميفينامك □ الأسبيرين (يستخدم لعلاج الألم، الالتهابات و ارتفاع درجة الحرارة) □ مكملات البوتاسيوم (أملاح البوتاسيوم) □ نورادرينالين (نورإيبينفرين) و الذي يستخدم لعلاج انخفاض ضغط الدم و مشاكل القلب □ الأدوية المخدرة □ كاربينوكسولون (يستخدم لعلاج القرحة) تناول نوراكتون مع الطعام والمشروبات: ابلع الدواء مع الماء و يفضل تناوله مع الطعام. الحمل والإرضاع: الحمل ً أو تخططين للإنجاب، تحدثي إلى طبيبك قبل تناول الدواء. إذا كنت حاملا الإرضاع يجب أن لا تتناولي نوراكتون إذا كنت مرضعة. قيادة السيارات واستعمال الآلات: قد يسبب نوراكتون الشعور بالدوار أو النعاس لذلك يجب أن تتأكد من عدم تأثير الدواء عليك أثناء القيادة أو استخدام الآلات. معلومات هامة عن بعض مكونات نوراكتون: يحتوي هذا الدواء على لاكتوز، فإذا أخبرك طبيبك أنك تعاني من عدم تحمل لبعض السكريات فإنه يجب عليك استشارته قبل تناول الدواء. التداخل مع بعض الفحوصات: إذا كنت ستقوم ببعض الفحوصات المتعلقة بوظائف الكبد أو ستقوم بالفحص لمرض السكري أو فحوصات أخرى متعلقة بمرض السكري ، فإن عليك إخبار طبيبك بأنك تتناول أقراص نوراكتون. قد تحتاج للتوقف عن تناول أقراص نوراكتون لمدة لا تقل عن ثلاثة أيام قبل إجراء فحص السكري. الفحوصات التي يجب القيام بها: قد يحتاج طبيبك للقيام ببعض الفحوصات لمراقبة مستوى السوائل و المواد الكيميائية في الجسم, خاصة إذا كنت من كبار السن أو تعاني من ضعف في وظائف الكلى أو الكبد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائما المرضى البالغين: □ فشل القلب الاحتقاني: ۱۰۰ ملغم في اليوم. جرعة المداومة هي ۲۰۰-۲٥ ملغم في اليوم. في الحالات المرضية الصعبة أو الشديدة قد تصل الجرعة إلى ٤۰۰ ملغم كحد أقصى. □ المتلازمة الكلائية: ۲۰۰-۱۰۰ ملغم في اليوم. □ تشمع الكبد مع احتباس في السوائل وتورم في البطن: ٤۰۰-۱۰۰ ملغم في اليوم. سوف يقرر الطبيب جرعة المداومة المناسبة لك. □ مرض سرطاني مع تورم في البطن: ۲۰۰-۱۰۰ ملغم في اليوم. سوف يقرر الطبيب جرعة المداومة المناسبة لك. في الحالات المرضية الشديدة قد تصل الجرعة إلى ٤۰۰ ملغم كحد أقصى. □ لتشخيص الألدوستيرونية الأولية: الفحص الطويل: ٤۰۰ ملغم لمدة ٤-۳ أسابيع. الفحص القصير: ٤۰۰ ملغم لمدة ٤ أيام. ً لإجراء عملية جراحية. إذا لم يتم إجراء عملية جراحية ، سوف يقرر □ لعلاج الألدوستيرونية الأولية: ٤۰۰-۱۰۰ ملغم في اليوم استعدادا الطبيب جرعة المداومة المناسبة لك. كبار السن (الكهول): سوف يقرر الطبيب الجرعة المناسبة لك. إذا كنت تعاني من ضعف شديد في وظائف الكبد أو الكلى ، سيقوم الطبيب بوصف جرعة مختلفة لك. الأطفال: ً على جرعة البداية الاعتيادية هي ۳ ملغم لكل كيلو غرام من وزن الطفل، تؤخذ على جرعات مقسمة. سوف يقوم الطبيب بتعديل الجرعة اعتمادا استجابتك للدواء. يمكن سحق القرص و يوضع في الطعام أو الشراب إذا احتاج الأمر لذلك. إذا تناولت نوراكتون أكثر مما يجب: اذا تناولت أنت أو شخص آخر الكثير من نوراكتون (أكثر من الجرعة المقررة) أو كنت تظن أن طفلك ابتلع أي من هذه الأقراص، فإن عليك التحدث إلى طبيبك أو اذهب إلى أقرب مستشفى على الفور. تشمل أعراض الجرعة الزائدة: نعاس، تشوش ذهني، غثيان أو تقيؤ، دوار، إسهال، انخفاض في مستوى الصوديوم في الدم، زيادة في مستوى البوتاسيوم (الأعراض: نخز، ضعف أو تعب غير اعتيادي، ضعف في العضلات، شلل مع فقدان تناغم حركة العضلة، تشنج عضلي). إذا نسيت تناول نوراكتون: إذا نسيت تناول الجرعة، عليك تناولها في أقرب وقت من تذكرها. تناول جرعتك التالية في موعدها. لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية. إذا توقفت عن تناول نوراكتون: □ من المهم الاستمرار في تناول نوراكتون إلى نهاية وقت المعالجة حتى لو شعرت بتحسن ،إلى حين أن يخبرك طبيبك بالتوقف عن تناوله. □ إذا توقفت عن تناول الدواء في وقت مبكر قد يؤدي هذا إلى تدهور حالتك المرضية. □ إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كغيره من الأدوية، قد يسبب نوراكتون آثارا يجب التوقف عن تناول نوراكتون والاتصال بطبيبك على الفور إذا حدثت معك الأعراض التالية: □ ارتفاع مستوى البوتاسيوم في الدم: يشمل الأعراض التالية: نفضان العضلات أو ضعفها، عدم انتظام ضربات القلب،التعب أو الضعف العام غير الاعتيادي، شلل مع أو بدون فقدان تناغم حركة العضلات، فشل الدورة الدموية) وخاصة إذا كنت تعاني من ضعف في وظائف الكلىاتصل بطبيبك على الفور إذا: □ لاحظت علامات تدل على تفاعل تحسسي (فرط الحساسية) مثل تورم في الوجه أو الشفاه أو اللسان أو الحلق، وصعوبة في التنفس أو البلع، صدمة أو هبوط في الجسم ، طفح جلدي أو حكة. ً أو إذا لاحظت أعراض أخرى غير مذكورة في عليك إخبار الطبيب أو الصيدلاني إذا حدثت لك أياً من الأعراض التالية أو إذا ازدادت سوءا النشرة: □ الدم: زيادة في مستويات اليوريا أو النيتروجين في الدم خاصة في الأشخاص الذين يعانون من فشل في وظائف الكلى.تغيير أنواع و أعداد خلايا الدم. إذا لاحظت زيادة حدوث الكدمات، نزيف في الأنف، التهاب الحلق أو إصابته بالعدوى، يجب إخبار الطبيب الذي قد يرغب في عمل بعض الفحوصات المخبرية للدم. □ الأيض و التغذية: انخفاض مستوى الصوديوم في الدم، وتغيرات على مستوى المواد الكيميائية في الجسم. □ الجهاز العصبي: عدم السيطرة على العضلات أو التنسيق بين حركتها، نعاس، دوخة، صداع، و التصرف بشكل غير ملائم. □ التأثير النفسي: تعب □ الكبد: تأثير سام على الكبد. □ المعدة والأمعاء: التهاب بطانة المعدة، نزيف في المعدة، قرحة في المعدة أو الأمعاء، مغص في البطن، إسهال، تقيؤ. □ الجلد: طفح جلدي بما في ذلك شحوب أو ظهور بقع حمراء مرتفعة على سطح الجلد غير منظمة مع حكة شديدة (الشرى) وفقدان الشعر، حكة وتقرح الجلد حول الشفتين و بقية الجسم (متلازمة ستيفنز جونسون)، انفصال الطبقة العليا من الجلد عن الطبقة السفلى في جميع أنحاء الجسم (تقشر الأنسجة المتموتة البشروية التسممي)، طفح جلدي وحمى وتورم (والتي قد تكون أعراض لأمر أكثر خطورة، طفح دوائي، كثرة اليوزينيات وأعراض شاملة) . □ العضلات والعظام: تليين العظام بسبب نقص فيتامين د. □ الكلى: الفشل الكلوي الحاد وخاصة في المرضى الذين لديهم اختلال في وظائف الكلى قبل البدء بتناول الدواء. □ الجهاز التناسلي: تضخم الثديين عند الرجال، تغيرات في طبقة الصوت، انخفاض الفاعلية الجنسية لدى الرجال، وانخفاض القدرة الجنسية، إيلام في الثدي، زيادة نمو الشعر عند الإناث، عدم انتظام الدورة الشهرية، التعرق. ً أو لاحظت أعراض أخرى غير ً من الآثار الجانبية المذكورة أعلاه أو إذا ازدادت هذه الأعراض سوءا أخبر طبيبك أو الصيدلي إذا لاحظت أيا مذكورة في النشرة:</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>□ يحفظ بعيدا ً عن الضوء والرطوبة. □ لا يحفظ بدرجة حرارة أعلى من &deg;۳۰م، يحفظ بعيدا □ لا ينبغي استعمال نوراكتون بعد تاريخ انتهاء الصلاحية الموجود على العلبة وعلى شريط الدواء. لا ينبغي التخلص من الأدوية من خلال مياه الصرف الصحي أو المنزلي. اسأل الصيدلاني عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. سوف تساعد هذه الإجراءات على حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>على ماذا يحتوي نوراكتون: المادة الفعالة هي سبايرونولاكتون. كل قرص يحتوي على ۲٥ ملغم من سبايرونولاكتون. المكونات الأخرى هي: فوسفات الكالسيوم ثنائي القاعدة اللامائي، لاكتوز، نشا الذرة، سلفات لوريل الصوديوم، ستيارات المغنيزيوم، سيليكا غروية لامائية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>□ أقراص نوراكتون ۲٥ ملغم هي أقراص بيضاء دائرية مسطحة حادة الحواف غير منقوشة من الطرفين. □ علب تحتوي على ۳۰ قرص من أقراص نوراكتون ۲٥ المحفوظة في أشرطة. □ علب تحتوي على ۱۰۰۰ قرص من أقراص نوراكتون ۲٥المحفوظة في أشرطة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>لمملكة العربية السعودية: للإبلاغ عن الأعراض الجانبية: المركزالوطني للتيقظ: فاكس: ،۰۰۹٦٦۱۱۲۰٥۷٦٦۲ مركز اتصال الهيئة العامة https://ade.sfda.gov.sa :الإلكتروني الموقع ،npc.drug@sfda.gov.sa :الإلكتروني البريد ،۱۹۹۹۹:)SFDA) والدواء ل</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             حزيران2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Noractone 25 mg Tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active Ingredient:
Each tablet contains Spironolactone 25 mg.
Inactive Ingredients:
Inactive ingredients(s) and amount (s) per unit dose:
Ingredient mg/Tab
Anhydrous Dibasic Calcium Phosphate 51.0
Lactose 88.6
Maize Strach 85.0
Sodium Lauryl Sulphate 2.5
Magnesium Stearate 1.4
Colloidal Anhydrous Silica 1.0
 *For a full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dull Red Shallow biconvex oblong film coated tablets, debossed with “MX4” on one side and plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>AVORES</strong> 400 mg film-coated tablets are indicated for the treatment of the following bacterial infections in patients of 18 years and older caused by bacteria susceptible to Moxifloxacin (see sections 4.4, 4.8 and 5.1). Moxifloxacin should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections or when these have failed:</p><p>&nbsp;</p><p>⦁ Acute bacterial sinusitis (adequately diagnosed)</p><p>⦁ Acute exacerbations of chronic bronchitis (adequately diagnosed)</p><p>⦁ Community acquired pneumonia, except severe cases</p><p>⦁ Mild to moderate pelvic inflammatory disease (i.e. infections of female upper genital tract, including salpingitis and endometritis), without an associated tubo-ovarian or pelvic abscess. AVORES 400 mg film-coated tablets are not recommended for use in monotherapy of mild to moderate pelvic inflammatory disease but should be given in combination with another appropriate antibacterial agent (e.g. a cephalosporin) due to increasing Moxifloxacin resistance of Neisseria gonorrhoeae unless Moxifloxacin-resistant Neisseria gonorrhoeae can be excluded (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p><strong>AVORES</strong> 400 mg film-coated tablets may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous Moxifloxacin for the following indications:</p><p>&nbsp;</p><p>⦁ Community-acquired pneumonia</p><p>⦁ Complicated skin and skin structure infections AVORES 400 mg film-coated tablets should not be used to initiate therapy for any type of skin and skin structure infection or in severe community-acquired pneumonia. Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Route of administration: Oral &ldquo;</p><p><strong><u>Posology (adults)</u></strong></p><p>The recommended dose is one 400 mg film-coated tablet once daily.</p><p><strong><em>Renal/hepatic impairment</em></strong></p><p>No adjustment of dosage is required in patients with mild to severely impaired renal function or in patients on chronic dialysis i.e. haemodialysis and continuous ambulatory peritoneal dialysis (see section 5.2 for more details).</p><p>There is insufficient data in patients with impaired liver function (see section 4.3).</p><p><strong><em>Other special populations</em></strong></p><p>No adjustment of dosage is required in the elderly and in patients with low bodyweight.</p><p><strong><em>Paediatric population</em></strong></p><p>Moxifloxacin is contraindicated in children and adolescents (&lt; 18 years). Efficacy and safety of Moxifloxacin in children and adolescents have not been established (see section 4.3).</p><p><strong><u>Method of administration</u></strong></p><p>The film-coated tablet should be swallowed whole with sufficient liquid and may be taken independent of meals.</p><p><strong><u>Duration of administration</u></strong></p><p><strong>AVORES</strong> 400 mg film-coated tablets should be used for the following treatment durations:</p><p>q&nbsp; Acute exacerbation of chronic obstructive pulmonary disese including bronchitis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;5 - 10 days&nbsp;</p><p>q&nbsp; Community acquired pneumonia&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10 days&nbsp;</p><p>q&nbsp; Acute bacterial sinusitis&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7 days&nbsp;</p><p>q&nbsp; Mild to moderate pelvic inflammatory disease&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;14 days&nbsp;</p><p>AVORES 400 mg film-coated tablets have been studied in clinical trials for up to 14 days treatment.</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Sequential (intravenous followed by oral) therapy</em></strong></p><p>In clinical studies with sequential therapy most patients switched from intravenous to oral therapy within 4 days (community-acquired pneumonia) or 6 days (complicated skin and skin structure infections). The recommended total duration of intravenous and oral treatment is 7 -14 days for community-acquired pneumonia and 7 -21 days for complicated skin and skin structure infections</p><p>The recommended dose (400 mg once daily) and duration of therapy for the indication being treated should not be exceeded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Hypersensitivity to Moxifloxacin, other quinolones or to any of the excipients listed in section 6.1.
	Pregnancy and lactation (see section 4.6).
	Patients below 18 years of age.
	Patients with a history of tendon disease/disorder related to quinolone treatment.
	Both in preclinical investigations and in humans, changes in cardiac electrophysiology have been observed following exposure to Moxifloxacin, in the form of QT prolongation. For reasons of drug safety, Moxifloxacin is therefore contraindicated in patients with:
	 Congenital or documented acquired QT prolongation
	 Electrolyte disturbances, particularly in uncorrected hypokalaemia
	 Clinically relevant bradycardia
	 Clinically relevant heart failure with reduced left-ventricular ejection fraction
	Previous history of symptomatic arrhythmias
	Moxifloxacin should not be used concurrently with other drugs that prolong the QT interval (see also section 4.5).
	Due to limited clinical data, Moxifloxacin is also contraindicated in patients with impaired liver function (Child Pugh C) and in patients with transaminases increase > 5fold ULN.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of moxifloxacin should be avoided in patients who have&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; experienced serious adverse reactions in the past when using quinolone or fluoroquinolone containing products (see section 4.8). Treatment of these patients with moxifloxacin should only be initiated in the absence of alternative treatment options and after careful benefit/risk assessment (see also section 4.3).</p><p>&nbsp;</p><p>The benefit of Moxifloxacin treatment especially in infections with a low degree of severity should be balanced with the information contained in the warnings and precautions section.</p><p><u>&nbsp;</u></p><p><u>Prolongation of QTc interval and potentially QTc-prolongation-related clinical conditions</u></p><p>Moxifloxacin has been shown to prolong the QTc interval on the electrocardiogram in some patients. In the analysis of ECGs obtained in the clinical trial program, QTc prolongation with Moxifloxacin was 6 msec &plusmn; 26 msec, 1.4% compared to baseline. As women tend to have a longer baseline QTc interval compared with men, they may be more sensitive to QTc-prolonging medications. Elderly patients may also be more susceptible to drug-associated effects on the QT interval.</p><p>Medication that can reduce potassium levels should be used with caution in patients receiving Moxifloxacin (see also sections 4.3 and 4.5).</p><p>Moxifloxacin should be used with caution in patients with ongoing proarrhythmic conditions (especially women and elderly patients), such as acute myocardial ischaemia or QT prolongation as this may lead to an increased risk for ventricular arrhythmias (incl. torsade de pointes) and cardiac arrest (see also section 4.3). The magnitude of QT prolongation may increase with increasing concentrations of the drug. Therefore, the recommended dose should not be exceeded.</p><p>If signs of cardiac arrhythmia occur during treatment with Moxifloxacin, treatment should be stopped and an ECG should be performed.</p><p><u>Hypersensitivity/allergic reactions</u></p><p>Hypersensitivity and allergic reactions have been reported for fluoroquinolones including Moxifloxacin after first administration. Anaphylactic reactions can progress to a life-threatening shock, even after the first administration. In these cases Moxifloxacin should be discontinued and suitable treatment (e.g. treatment for shock) initiated.</p><p><u>Severe liver disorders</u></p><p>Cases of fulminant hepatitis potentially leading to liver failure (including fatal cases) have been reported with Moxifloxacin (see section 4.8). Patients should be advised to contact their doctor prior to continuing treatment if signs and symptoms of fulminant hepatic disease develop such as rapidly developing asthenia associated with jaundice, dark urine, bleeding tendency or hepatic encephalopathy.</p><p>Liver function tests/investigations should be performed in cases where indications of liver dysfunction occur.</p><p><u>Severe cutaneous adverse reactions</u></p><p>Severe cutaneous adverse reactions (SCARs) including toxic epidermal necrolysis (TEN: also known as Lyell&#39;s syndrome), Stevens Johnson syndrome (SJS) and Acute Generalised Exanthematous Pustulosis (AGEP), which could be life-threatening or fatal, have been reported with moxifloxacin (see section 4.8). At the time of prescription, patients should be advised of the signs and symptoms of severe skin reactions and be closely monitored. If signs and symptoms suggestive of these reactions appear, moxifloxacin should be discontinued immediately, and an alternative treatment should be considered. If the patient has developed a serious reaction such as SJS, TEN or AGEP with the use of moxifloxacin, treatment with moxifloxacin must not be restarted in this patient at any time.</p><p><u>Patients predisposed to seizures</u></p><p>Quinolones are known to trigger seizures. Use should be with caution in patients with CNS disorders or in the presence of other risk factors which may predispose to seizures or lower the seizure threshold. In case of seizures, treatment with Moxifloxacin should be discontinued and appropriate measures instituted.</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>Prolonged, disabling and potentially irreversible serious adverse drug reactions</u></p><p>Very rare cases of prolonged (continuing months or years), disabling and potentially irreversible serious adverse drug reactions affecting different, sometimes multiple, body systems (musculoskeletal, nervous, psychiatric and senses) have been reported in patients receiving quinolones and fluoroquinolones irrespective of their age and pre-existing risk factors. Moxifloxacin should be discontinued immediately at the first signs or symptoms of any serious adverse reaction and patients should be advised to contact their prescriber for advice.</p><p><u>Peripheral neuropathy</u></p><p>Cases of sensory or sensorimotor polyneuropathy resulting in paraesthesias, hypoaesthesias, dysaesthesias, or weakness have been reported in patients receiving quinolones including Moxifloxacin. Patients under treatment with Moxifloxacin should be advised to inform their doctor prior to continuing treatment if symptoms of neuropathy such as pain, burning, tingling, numbness, or weakness develop in order to prevent the development of potentially irreversible condition (see section 4.8).</p><p><u>Psychiatric reactions</u></p><p>Psychiatric reactions may occur even after the first administration of quinolones, including Moxifloxacin. In very rare cases depression or psychotic reactions have progressed to suicidal thoughts and self-injurious behaviour such as suicide attempts (see section 4.8). In the event that the patient develops these reactions, Moxifloxacin should be discontinued and appropriate measures instituted. Caution is recommended if Moxifloxacin is to be used in psychotic patients or in patients with history of psychiatric disease.</p><p><u>Antibiotic-associated diarrhoea incl. colitis</u></p><p>Antibiotic-associated diarrhoea (AAD) and antibiotic-associated colitis (AAC), including pseudomembranous colitis and <em>Clostridium difficile</em>-associated diarrhoea, has been reported in association with the use of broad-spectrum antibiotics including Moxifloxacin and may range in severity from mild diarrhoea to fatal colitis. Therefore, it is important to consider this diagnosis in patients who develop serious diarrhoea during or after the use of Moxifloxacin. If AAD or AAC is suspected or confirmed, ongoing treatment with antibacterial agents, including Moxifloxacin, should be discontinued and adequate therapeutic measures should be initiated immediately. Furthermore, appropriate infection control measures should be undertaken to reduce the risk of transmission. Drugs inhibiting peristalsis are contraindicated in patients who develop serious diarrhoea.</p><p><u>Patients with myasthenia gravis</u></p><p>Moxifloxacin should be used with caution in patients with myasthenia gravis because the symptoms can be exacerbated.</p><p><u>Tendon inflammation, tendon rupture</u></p><p>Tendon inflammation and rupture (especially but not limited to Achilles tendon), sometimes bilateral, may occur with quinolone therapy including Moxifloxacin, even within 48 hours of starting treatment and have been reported up to several months after discontinuation of therapy. The risk of tendinitis and tendon rupture is increased in older patients, patients with renal impairment, patients with solid organ transplants, and those treated concurrently with corticosteroids. Therefore, concomitant use of corticosteroids should be avoided.</p><p>At the first sign of tendinitis (e.g. painful swelling, inflammation) the treatment with moxifloxacin should be discontinued and alternative treatment should be considered. The affected limb(s) should be appropriately treated (e.g. immobilisation). Corticosteroids should not be used if signs of tendinopathy occur.</p><p><u>Aortic aneurysm and dissection, and heart valve regurgitation/incompetence</u></p><p>Epidemiologic studies report an increased risk of aortic aneurysm and dissection, particularly in elderly patients, and of aortic and mitral valve regurgitation after intake of fluoroquinolones. Cases of aortic aneurysm and dissection, sometimes complicated by rupture (including fatal ones), and of regurgitation/incompetence of any of the heart valves have been reported in patients receiving fluoroquinolones (see section 4.8).</p><p>Therefore, fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in patients with positive family history of aneurysm disease or congenital heart valve disease, or in patients diagnosed with pre-existing aortic aneurysm and/or dissection or heart valve disease, or in presence of other risk factors or conditions predisposing</p><p>- for both aortic aneurysm and dissection and heart valve regurgitation/incompetence (e.g. connective tissue disorders such as Marfan syndrome or Ehlers-Danlos syndrome, Turner syndrome, Beh<!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:5.25pt;height:11.25pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ssalayta/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="7" height="15" src="file:///C:/Users/ssalayta/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />et&#39;s disease, hypertension, rheumatoid arthritis) or additionally</p><p>- for aortic aneurysm and dissection (e.g. vascular disorders such as Takayasu arteritis or giant cell arteritis, or known atherosclerosis, or Sj&ouml;gren&#39;s syndrome) or additionally</p><p>- for heart valve regurgitation/incompetence (e.g. infective endocarditis).</p><p>The risk of aortic aneurysm and dissection, and their rupture may also be increased in patients treated concurrently with systemic corticosteroids.</p><p>In case of sudden abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department.</p><p>Patients should be advised to seek immediate medical attention in case of acute dyspnoea, new onset of heart palpitations, or development of oedema of the abdomen or lower extremities.</p><p>&nbsp;</p><p><u>Patients with renal impairment</u></p><p>Elderly patients with renal disorders should use Moxifloxacin with caution if they are unable to maintain adequate fluid intake, because dehydration may increase the risk of renal failure.</p><p><u>Vision disorders</u></p><p>If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately (see sections 4.7 and 4.8).</p><p><u>Dysglycemia</u></p><p>As with all fluoroquinolones, disturbances in blood glucose, including both hypoglycemia and hyperglycemia have been reported with Moxifloxacin. In Moxifloxacin-treated patients, dysglycemia occurred predominantly in elderly diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g. sulfonylurea) or with insulin. Cases of hypoglycaemic coma have been reported. In diabetic patients, careful monitoring of blood glucose is recommended (see section 4.8).</p><p><u>Prevention of photosensitivity reactions</u></p><p>Quinolones have been shown to cause photosensitivity reactions in patients. However, studies have shown that Moxifloxacin has a lower risk to induce photosensitivity. Nevertheless patients should be advised to avoid exposure to either UV irradiation or extensive and/or strong sunlight during treatment with Moxifloxacin.</p><p><u>Patients with glucose-6-phosphate dehydrogenase deficiency</u></p><p>Patients with a family history of, or actual glucose-6-phosphate dehydrogenase deficiency are prone to haemolytic reactions when treated with quinolones. Therefore, Moxifloxacin should be used with caution in these patients.</p><p><u>Patients with pelvic inflammatory disease</u></p><p>For patients with complicated pelvic inflammatory disease (e.g. associated with a tubo-ovarian or pelvic abscess), for whom an intravenous treatment is considered necessary, treatment with AVORES 400 mg film-coated tablets is not recommended.</p><p>Pelvic inflammatory disease may be caused by fluoroquinolone-resistant Neisseria gonorrhoeae. Therefore in such cases empirical Moxifloxacin should be co-administered with another appropriate antibiotic (e.g. a cephalosporin) unless Moxifloxacin-resistant Neisseria gonorrhoeae can be excluded. If clinical improvement is not achieved after 3 days of treatment, the therapy should be reconsidered.</p><p><u>Patients with special cSSSi</u></p><p>Clinical efficacy of intravenous Moxifloxacin in the treatment of severe burn infections, fasciitis and diabetic foot infections with osteomyelitis has not been established.</p><p><u>Interference with biological tests</u></p><p>Moxifloxacin therapy may interfere with the <em>Mycobacterium </em>spp. culture test by suppression of mycobacterial growth causing false negative results in samples taken from patients currently receiving Moxifloxacin.</p><p><u>Patients with MRSA infections</u></p><p>Moxifloxacin is not recommended for the treatment of MRSA infections. In case of a suspected or confirmed infection due to MRSA, treatment with an appropriate antibacterial agent should be started (see section 5.1).</p><p><u>Paediatric population</u></p><p>Due to adverse effects on the cartilage in juvenile animals (see section 5.3) the use of Moxifloxacin in children and adolescents &lt; 18 years is contraindicated (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Interactions with medicinal products</u></p><p>An additive effect on QT interval prolongation of Moxifloxacin and other medicinal products that may prolong the QTc interval cannot be excluded. This might lead to an increased risk of ventricular arrhythmias, including torsade de pointes. Therefore, co-administration of Moxifloxacin with any of the following medicinal products is contraindicated (see also section 4.3):</p><p>q&nbsp; Anti-arrhythmics class IA (e.g. quinidine, hydroquinidine, disopyramide)</p><p>q&nbsp; Anti-arrhythmics class III (e.g. amiodarone, sotalol, dofetilide, ibutilide)</p><p>q&nbsp; Antipsychotics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride)</p><p>q&nbsp; Tricyclic antidepressive agents</p><p>q&nbsp; Certain antimicrobial agents (saquinavir, sparfloxacin, erythromycin IV, pentamidine, antimalarials particularly halofantrine)</p><p>q&nbsp; Certain antihistaminics (terfenadine, astemizole, mizolastine)</p><p>q&nbsp; Others (cisapride, vincamine IV, bepridil, diphemanil).</p><p>&nbsp;</p><p>Moxifloxacin should be used with caution in patients who are taking medication that can reduce potassium levels (e.g. loop and thiazide-type diuretics, laxatives and enemas [high doses], corticosteroids, amphotericin B) or medication that is associated with clinically significant bradycardia.</p><p>An interval of about 6 hours should be left between administration of agents containing bivalent or trivalent cations (e.g. antacids containing magnesium or aluminium, didanosine tablets, sucralfate and agents containing iron or zinc) and administration of Moxifloxacin.</p><p>Concomitant administration of charcoal with an oral dose of 400 mg Moxifloxacin led to a pronounced prevention of drug absorption and a reduced systemic availability of the drug by more than 80%. Therefore, the concomitant use of these two drugs is not recommended (except for overdose cases, see also section 4.9).</p><p>After repeated dosing in healthy volunteers, Moxifloxacin increased C<sub>max</sub> of digoxin by approximately 30% without affecting AUC or trough levels. No precaution is required for use with digoxin.</p><p>In studies conducted in diabetic volunteers, concomitant administration of oral Moxifloxacin with glibenclamide resulted in a decrease of approximately 21% in the peak plasma concentrations of glibenclamide. The combination of glibenclamide and Moxifloxacin could theoretically result in a mild and transient hyperglycaemia. However, the observed pharmacokinetic changes for glibenclamide did not result in changes of the pharmacodynamic parameters (blood glucose, insulin). Therefore, no clinically relevant interaction was observed between Moxifloxacin and glibenclamide.</p><p><u>Changes in INR</u></p><p>A large number of cases showing an increase in oral anticoagulant activity have been reported in patients receiving antibacterial agents, especially fluoroquinolones, macrolides, tetracyclines, cotrimoxazole and some cephalosporins. The infectious and inflammatory conditions, age and general status of the patient appear to be risk factors. Under these circumstances, it is difficult to evaluate whether the infection or the treatment caused the INR (international normalised ratio) disorder. A precautionary measure would be to more frequently monitor the INR. If necessary, the oral anticoagulant dosage should be adjusted as appropriate.</p><p>Clinical studies have shown no interactions following concomitant administration of Moxifloxacin with: ranitidine, probenecid, oral contraceptives, calcium supplements, morphine administered parenterally, theophylline, cyclosporine or itraconazole.</p><p>In vitro studies with human cytochrome P450 enzymes supported these findings. Considering these results a metabolic interaction via cytochrome P450 enzymes is unlikely.</p><p><u>Interaction with food</u></p><p>Moxifloxacin has no clinically relevant interaction with food including dairy products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>The safety of Moxifloxacin in human pregnancy has not been evaluated. Animal studies have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of immature animals and reversible joint injuries described in children receiving some fluoroquinolones, Moxifloxacin must not be used in pregnant women (see section 4.3).</p><p><u>Breastfeeding</u></p><p>There is no data available in lactating or nursing women. Preclinical data indicate that small amounts of Moxifloxacin are secreted in milk. In the absence of human data and due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of immature animals, breast-feeding is contraindicated during Moxifloxacin therapy (see section 4.3).</p><p><u>Fertility</u></p><p>Animal studies do not indicate impairment of fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of Moxifloxacin on the ability to drive and use machines have been performed. However, fluoroquinolones including Moxifloxacin may result in an impairment of the patient&#39;s ability to drive or operate machinery due to CNS reactions (e.g. dizziness; acute, transient loss of vision, see section 4.8) or acute and short-lasting loss of consciousness (syncope, see section 4.8). Patients should be advised to see how they react to Moxifloxacin before driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions based on all clinical trials with Moxifloxacin 400 mg (oral and sequential therapy) sorted by frequencies are listed below:</p><p>Apart from nausea and diarrhoea all adverse reactions were observed at frequencies below 3%.</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as:</p><p>q&nbsp; Common (&ge; 1/100 to &lt; 1/10)</p><p>q&nbsp; Uncommon (&ge; 1/1,000 to &lt; 1/100)</p><p>q&nbsp; Rare (&ge; 1/10,000 to &lt; 1/1,000)</p><p>q&nbsp; Very rare (&lt; 1/10,000)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:778px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p></td><td style="vertical-align:top"><p><strong>Not Known </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections</strong><strong> </strong><strong>and infestations</strong></p></td><td style="vertical-align:top"><p>Superinfections due to resistant bacteria or fungi e.g. oral&nbsp;&nbsp; and vaginal candidiasis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood</strong><strong> </strong><strong>and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaemia Leucopenia(s) Neutropenia Thrombocytopenia Thrombocythemia Blood eosinophilia Prothrombin time prolonged/INR increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Prothrombin level increased/INR decreased</p><p>Agranulocytosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Allergic reaction (see section 4.4)</p></td><td style="vertical-align:top"><p>Anaphylaxis incl. very rarely life-threatening shock (see section 4.4)</p><p>Allergic oedema/ angiooedema (incl. laryngeal oedema, potentially life-threatening, see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Syndrome of inappropriate antidiuretic hormone secretion (SIADH)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperlipidemia</p></td><td style="vertical-align:top"><p>Hyperglycemia</p><p>Hyperuricemia</p></td><td style="vertical-align:top"><p>Hypoglycemia</p><p>Hypoglycaemic coma</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders*</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anxiety reactions</p><p>Psychomotor hyperactivity/ agitation</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Emotional lability Depression (in very rare cases potentially culminating in self-injurious behaviour, such as suicidal ideations/thoughts, or suicide attempts, see section 4.4) Hallucination</p><p>Delirium</p></td><td style="vertical-align:top"><p>Depersonalization</p><p>Psychotic reactions (potentially culminating in self-injurious behaviour, such as suicidal ideations/ thoughts,or suicide attempts, see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders*</strong></p></td><td style="vertical-align:top"><p>Headache</p><p>Dizziness</p></td><td style="vertical-align:top"><p>Par- and Dysaesthesia</p><p>Taste disorders (incl. ageusia in very rare cases)</p><p>Confusion and disorientation</p><p>Sleep disorders (predominantly insomnia)</p><p>Tremor</p><p>Vertigo</p><p>Somnolence</p></td><td style="vertical-align:top"><p>Hypoaesthesia</p><p>Smell disorders (incl. anosmia)</p><p>Abnormal dreams</p><p>Disturbed coordination (incl. gait disturbances, esp. due to dizziness or vertigo)</p><p>Seizures incl. grand mal convulsions (see section 4.4)</p><p>Disturbed attention</p><p>Speech disorders</p><p>Amnesia</p><p>&nbsp;</p><p>Peripheral neuropathy and polyneuropathy</p></td><td style="vertical-align:top"><p>Hyperaesthesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders*</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual disturbances incl. diplopia and blurred vision (especially in the course of CNS reactions, see section 4.4)</p></td><td style="vertical-align:top"><p>Photophobia</p></td><td style="vertical-align:top"><p>Transient loss of vision (especially in the course of CNS reactions, see sections 4.4 and 4.7)</p><p>Uveitis and bilateral acute iris transillumination (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders*</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tinnitus</p><p>Hearing impairment incl. deafness (usually reversible)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders**</strong></p></td><td style="vertical-align:top"><p>QT prolongation in patients with hypokalaemia (see sections 4.3 and 4.4)</p></td><td style="vertical-align:top"><p>QT prolongation (see section 4.4)</p><p>Palpitations</p><p>Tachycardia</p><p>Atrial fibrillation</p><p>Angina pectoris</p></td><td style="vertical-align:top"><p>Ventricular tachyarrhythmias</p><p>Syncope (i.e., acute and short lasting loss of consciousness)</p></td><td style="vertical-align:top"><p>Unspecified arrhythmias</p><p>Torsade de Pointes (see section 4.4)</p><p>Cardiac arrest (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders**</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vasodilatation</p></td><td style="vertical-align:top"><p>Hypertension</p><p>Hypotension</p></td><td style="vertical-align:top"><p>Vasculitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnea (including asthmatic conditions)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Nausea</p><p>Vomiting</p><p>Gastrointestinal and abdominal pains</p><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Decreased appetite and food intake</p><p>Constipation</p><p>Dyspepsia</p><p>Flatulence</p><p>Gastritis</p><p>Increased amylase</p></td><td style="vertical-align:top"><p>Dysphagia</p><p>Stomatitis</p><p>Antibiotic associated colitis (incl. pseudo-membranous colitis, in very rare cases associated with life-threatening complications, see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>Increase in transaminases</p></td><td style="vertical-align:top"><p>Hepatic impairment (incl. LDH increase)</p><p>Increased bilirubin</p><p>Increased gamma-glutamyl-transferase</p><p>Increase in blood alkaline phosphatase</p></td><td style="vertical-align:top"><p>Jaundice</p><p>Hepatitis (predominantly cholestatic)</p></td><td style="vertical-align:top"><p>Fulminant hepatitis potentially leading to life-threatening liver failure (incl. fatal cases, see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pruritus</p><p>Rash</p><p>Urticaria</p><p>Dry skin</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bullous skin reactions like Stevens-Johnson syndrome or toxic epidermal necrolysis (potentially life-threatening, see section 4.4)</p></td><td style="vertical-align:top"><p>Acute Generalised Exanthematous Pustulosis (AGEP)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders**</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia</p><p>Myalgia</p></td><td style="vertical-align:top"><p>Tendonitis (see section 4.4)</p><p>Muscle cramp</p><p>Muscle twitching</p><p>Muscle weakness</p></td><td style="vertical-align:top"><p>Tendon rupture (see section 4.4)</p><p>Arthritis</p><p>Muscle rigidity</p><p>Exacerbation of symptoms of myasthenia gravis (see section 4.4)</p></td><td style="vertical-align:top"><p>Rhabdomyolysis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dehydration</p></td><td style="vertical-align:top"><p>Renal impairment (incl. increase in BUN and creatinine)</p><p>Renal failure (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions*</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Feeling unwell (predominantly asthenia or fatigue)</p><p>Painful conditions (incl. pain in back, chest, pelvic and extremities)</p><p>Sweating</p></td><td style="vertical-align:top"><p>Oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>*Very rare cases of prolonged (up to months or years), disabling and potentially irreversible serious drug reactions affecting several, sometimes multiple, system organ classes and senses (including reactions such as tendonitis, tendon rupture, arthralgia, pain in extremities, gait disturbance, neuropathies associated with paraesthesia, depression, fatigue, memory impairment, sleep disorders, and impairment of hearing, vision, taste and smell) have been reported in association with the use of quinolones and fluoroquinolones in some cases irrespective of pre-existing risk factors (see section 4.4).</p><p>**Cases of aortic aneurysm and dissection, sometimes complicated by rupture (including fatal ones), and of regurgitation/incompetence of any of the heart valves have been reported in patients receiving fluoroquinolones (see section 4.4).</p><p>There have been very rare cases of the following side effects reported following treatment with other fluoroquinolones, which might possibly also occur during treatment with moxifloxacin: increased intracranial pressure (including pseudotumor cerebri), hypernatraemia, hypercalcaemia, haemolytic anaemia, photosensitivity reactions (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>To report any side effect (s):</u></p><p>&nbsp;&nbsp;&nbsp; Saudi Arabia: National Pharmacovigilance &amp; Drug Safety Centre (NPC)</p><p>To report any side effect(s): The</p><p>National Pharmacovigilance Center (NPC):</p><p>Fax: +966-11-205-7662,</p><p>SFDA Call Center: 19999,</p><p>E-mail: npc.drug@sfda.gov.sa,</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: http://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific countermeasures after accidental overdose are recommended. In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation. Concomitant administration of charcoal with a dose of 400 mg oral Moxifloxacin will reduce systemic availability of the drug by more than 80%. The use of charcoal early during absorption may be useful to prevent excessive increase in the systemic exposure to Moxifloxacin in cases of oral overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group:<strong> </strong>Quinolone antibacterials, fluoroquinolones</p><p><strong>&nbsp;</strong>ATC Code: J01MA14</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Mechanism of action</u></p><p>Moxifloxacin has in vitro activity against a wide range of Gram-positive and Gram-negative pathogens.</p><p>The bactericidal action of Moxifloxacin results from the inhibition of both type II topoisomerases (DNA gyrase and topoisomerase IV) required for bacterial DNA replication, transcription and repair. It appears that the C8-methoxy moiety contributes to enhanced activity and lower selection of resistant mutants of Gram-positive bacteria compared to the C8-H moiety. The presence of the bulky bicycloamine substituent at the C-7 position prevents active efflux, associated with the <em>nor</em>A or <em>pmr</em>A genes seen in certain Gram-positive bacteria.</p><p>Pharmacodynamic investigations have demonstrated that Moxifloxacin exhibits a concentration dependent killing rate. Minimum bactericidal concentrations (MBC) were found to be in the range of the minimum inhibitory concentrations (MIC).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Effect on the intestinal flora in humans</u></p><p>The following changes in the intestinal flora were seen in volunteers following oral administration of Moxifloxacin: <em>Escherichia coli</em>, <em>Bacillus spp.</em>, <em>Enterococcus spp</em>., and <em>Klebsiella spp</em>. were reduced, as were the anaerobes <em>Bacteroides vulgatus</em>, <em>Bifidobacterium spp</em>., <em>Eubacterium spp</em>., and <em>Peptostreptococcus spp</em>.. For <em>Bacteroides fragilis</em> there was an increase. These changes returned to normal within two weeks.</p><p><u>Mechanism of resistance</u></p><p>Resistance mechanisms that inactivate penicillins, cephalosporins, aminoglycosides, macrolides and tetracyclines do not interfere with the antibacterial activity of Moxifloxacin. Other resistance mechanisms such as permeation barriers (common in <em>Pseudomonas aeruginosa</em>) and efflux mechanisms may also affect susceptibility to Moxifloxacin.</p><p>In vitro resistance to Moxifloxacin is acquired through a stepwise process by target site mutations in both type II topoisomerases, DNA gyrase and topoisomerase IV. Moxifloxacin is a poor substrate for active efflux mechanisms in Gram-positive organisms.</p><p>Cross-resistance is observed with other fluoroquinolones. However, as Moxifloxacin inhibits both topoisomerase II and IV with similar activity in some Gram-positive bacteria, such bacteria may be resistant to other quinolones, but susceptible to Moxifloxacin.</p><p><u>Breakpoints</u></p><p>EUCAST clinical MIC and disk diffusion breakpoints for Moxifloxacin (01.01.2012):</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Organism</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Susceptible</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resistant</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus spp.</em></p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 24 mm</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l</p><p>&lt; 21 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>S. pneumoniae</em></p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 22 mm</p></td><td style="vertical-align:top"><p>&gt; 0.5 mg/l</p><p>&ge; 22 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus</em> Groups A, B, C, G</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 18 mm</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l</p><p>&lt; 15 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>H. influenzae</em></p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 25 mm</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 25 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>M. catarrhalis</em></p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 23 mm</p></td><td style="vertical-align:top"><p>&gt; 0.5 mg/l</p><p>&lt; 23 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriaceae</em></p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 20 mm</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l</p><p>&lt; 17 mm</p></td></tr><tr><td style="vertical-align:top"><p>Non-species related breakpoints*</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l</p><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* Non-species related breakpoints have been determined mainly on the basis of pharmacokinetic/pharmacodynamic data and are independent of MIC distributions of specific species. They are for use only for species that have not been given a species-specific breakpoint and are not for use with species where interpretative criteria remain to be determined.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Microbiological Susceptibility</u></p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information of resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought where the local prevalence of resistance is such that utility of the agent in at least some types of infections is questionable.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly susceptible species</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Gardnerella vaginalis</em></p><p><em>Staphylococcus aureus</em>* (methicillin-susceptible)</p><p><em>Streptococcus agalactiae</em> (Group B)</p><p>Streptococcus milleri group* (<em>S. anginosus, S. constellatus and S. intermedius</em>)</p><p><em>Streptococcus pneumoniae</em>*</p><p><em>Streptococcus pyogenes</em>* (Group A)</p><p><em>Streptococcus viridans</em> group (<em>S. viridans, S. mutans, S. mitis, S. sanguinis, S. salivarius, S. thermophilus</em>)</p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Acinetobacter baumanii </em></p><p><em>Haemophilus influenzae* </em></p><p><em>Haemophilus parainfluenzae</em>*</p><p><em>Legionella pneumophila</em></p><p><em>Moraxella (Branhamella) catarrhalis</em>*</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p><em>Fusobacterium spp. </em></p><p><em>Prevotella spp.</em></p></td></tr><tr><td style="vertical-align:top"><p><u>&ldquo;Other&rdquo; micro-organisms</u></p><p><em>Chlamydophila (Chlamydia) pneumoniae* </em></p><p><em>Chlamydia trachomatis*</em></p><p><em>Coxiella burnetii</em></p><p><em>Mycoplasma genitalium</em></p><p><em>Mycoplasma hominis</em></p><p><em>Mycoplasma pneumoniae*</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Species for which acquired resistance may be a problem</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Enterococcus faecalis*</em></p><p><em>Enterococcus faecium* </em></p><p><em>Staphylococcus aureus (methicillin-resistant)<sup>+</sup></em></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Enterobacter cloacae* </em></p><p><em>Escherichia coli</em><em><sup>*#</sup></em></p><p><em>Klebsiella pneumoniae</em><em><sup>*#</sup></em></p><p><em>Klebsiella oxytoca </em></p><p><em>Neisseria gonorrhoeae</em><em><sup>*+</sup></em></p><p><em>Proteus mirabilis*</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p><em>Bacteroides fragilis*</em></p><p><em>Peptostreptococcus spp.*</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Inherently resistant organisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Pseudomonas aeruginosa</em></p></td></tr><tr><td style="vertical-align:top"><p>*Activity has been satisfactorily demonstrated in susceptible strains in clinical studies in the approved clinical indications.</p><p>&nbsp;</p><p>#ESBL-producing strains are commonly resistant to fluoroquinolones</p><p>+Resistance rate &gt; 50% in one or more countries</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption and Bioavailability</u></p><p>Following oral administration Moxifloxacin is rapidly and almost completely absorbed. The absolute bioavailability amounts to approximately 91%.</p><p>Pharmacokinetics are linear in the range of 50 - 800 mg single dose and up to 600 mg once daily dosing over 10 days. Following a 400 mg oral dose peak concentrations of 3.1 mg/l are reached within 0.5 - 4 h post administration. Peak and trough plasma concentrations at steady-state (400 mg once daily) were 3.2 and 0.6 mg/l, respectively. At steady-state the exposure within the dosing interval is approximately 30% higher than after the first dose.</p><p><u>Distribution</u></p><p>Moxifloxacin is distributed to extravascular spaces rapidly; after a dose of 400 mg an AUC of 35 m∙gh/l is observed. The steady-state volume of distribution (Vss) is approximately 2 l/kg. In vitro and ex vivo experiments showed a protein binding of approximately 40 - 42% independent of the concentration of the drug. Moxifloxacin is mainly bound to serum albumin.</p><p>The following peak concentrations (geometric mean) were observed following administration of a single oral dose of 400 mg Moxifloxacin:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Tissue</strong></p></td><td style="vertical-align:top"><p><strong>Concentration</strong></p></td><td style="vertical-align:top"><p><strong>Site: Plasma ratio</strong></p></td></tr><tr><td style="vertical-align:top"><p>Plasma</p></td><td style="vertical-align:top"><p>3.1 mg/l</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Saliva</p></td><td style="vertical-align:top"><p>3.6 mg/l</p></td><td style="vertical-align:top"><p>0.75 - 1.3</p></td></tr><tr><td style="vertical-align:top"><p>Blister fluid</p></td><td style="vertical-align:top"><p>1.6<sup>1</sup> mg/l</p></td><td style="vertical-align:top"><p>1.7<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Bronchial mucosa</p></td><td style="vertical-align:top"><p>5.4 mg/kg</p></td><td style="vertical-align:top"><p>1.7 - 2.1</p></td></tr><tr><td style="vertical-align:top"><p>Alveolar macrophages</p></td><td style="vertical-align:top"><p>56.7 mg/kg</p></td><td style="vertical-align:top"><p>18.6 - 70.0</p></td></tr><tr><td style="vertical-align:top"><p>Epithelial lining fluid</p></td><td style="vertical-align:top"><p>20.7 mg/l</p></td><td style="vertical-align:top"><p>5 - 7</p></td></tr><tr><td style="vertical-align:top"><p>Maxillary sinus</p></td><td style="vertical-align:top"><p>7.5 mg/kg</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td style="vertical-align:top"><p>Ethmoid sinus</p></td><td style="vertical-align:top"><p>8.2 mg/kg</p></td><td style="vertical-align:top"><p>2.1</p></td></tr><tr><td style="vertical-align:top"><p>Nasal polyps</p></td><td style="vertical-align:top"><p>9.1 mg/kg</p></td><td style="vertical-align:top"><p>2.6</p></td></tr><tr><td style="vertical-align:top"><p>Interstitial fluid</p></td><td style="vertical-align:top"><p>1.0<sup>2</sup> mg/l</p></td><td style="vertical-align:top"><p>0.8 - 1.4<sup>2,3</sup></p></td></tr><tr><td style="vertical-align:top"><p>Female genital tract*</p></td><td style="vertical-align:top"><p>10.2<sup>4</sup> mg/kg</p></td><td style="vertical-align:top"><p>1.72<sup>4</sup></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;* intravenous administration of a single 400 mg dose</p><p><sup>1</sup> 10 h after administration</p><p><sup>2 </sup>unbound concentration</p><p><sup>3</sup> from 3 h up to 36 h post dose</p><p><sup>4</sup> at the end of infusion</p><p><u>Biotransformation</u></p><p>Moxifloxacin undergoes Phase II biotransformation and is excreted via renal and biliary/faecal pathways as unchanged drug as well as in the form of a sulpho-compound (M1) and a glucuronide (M2). M1 and M2 are the only metabolites relevant in humans, both are microbiologically inactive.</p><p>In clinical Phase I and in vitro studies no metabolic pharmacokinetic interactions with other drugs undergoing Phase I biotransformation involving cytochrome P450 enzymes were observed. There is no indication of oxidative metabolism.</p><p><u>Elimination</u></p><p>Moxifloxacin is eliminated from plasma with a mean terminal half life of approximately 12 hours. The mean apparent total body clearance following a 400 mg dose ranges from 179 to 246 ml/min. Renal clearance amounted to about 24 - 53 ml/min suggesting partial tubular reabsorption of the drug from the kidneys.</p><p>After a 400 mg dose, recovery from urine (approximately 19% for unchanged drug, approximately 2.5% for M1, and approximately 14% for M2) and faeces (approximately 25% of unchanged drug, approximately 36% for M1, and no recovery for M2) totalled to approximately 96%.</p><p>Concomitant administration of Moxifloxacin with ranitidine or probenecid did not alter renal clearance of the parent drug.</p><p><em>Elderly and patients with low body weight</em></p><p>Higher plasma concentrations are observed in healthy volunteers with low body weight (such as women) and in elderly volunteers.</p><p><em>Renal impairment</em></p><p>The pharmacokinetic properties of Moxifloxacin are not significantly different in patients with renal impairment (including creatinine clearance &gt; 20 ml/min/1.73 m<sup>2</sup>). As renal function decreases, concentrations of the M2 metabolite (glucuronide) increase by up to a factor of 2.5 (with a creatinine clearance of &lt; 30 ml/min/1.73 m<sup>2</sup>).</p><p><em>Hepatic impairment</em></p><p>On the basis of the pharmacokinetic studies carried out so far in patients with liver failure (Child Pugh A, B), it is not possible to determine whether there are any differences compared with healthy volunteers. Impaired liver function was associated with higher exposure to M1 in plasma, whereas exposure to parent drug was comparable to exposure in healthy volunteers. There is insufficient experience in the clinical use of Moxifloxacin in patients with impaired liver function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects on the haematopoetic system (slight decreases in the number of erythrocytes and platelets) were seen in rats and monkeys. As with other quinolones, hepatotoxicity (elevated liver enzymes and vacuolar degeneration) was seen in rats, monkeys and dogs. In monkeys CNS toxicity (convulsions) occurred. These effects were seen only after treatment with high doses of Moxifloxacin or after prolonged treatment.</p><p>Moxifloxacin, like other quinolones, was genotoxic in in vitro tests using bacteria or mammalian cells. Since these effects can be explained by an interaction with the gyrase in bacteria and - at higher concentrations - by an interaction with the topoisomerase II in mammalian cells, a threshold concentration for genotoxicity can be assumed. In in vivo tests, no evidence of genotoxicity was found despite the fact that very high Moxifloxacin doses were used. Thus, a sufficient margin of safety to the therapeutic dose in man can be provided. Moxifloxacin was non-carcinogenic in an initiation-promotion study in rats.</p><p>Many quinolones are photoreactive and can induce phototoxic, photomutagenic and photocarcinogenic effects. In contrast, Moxifloxacin was proven to be devoid of phototoxic and photogenotoxic properties when tested in a comprehensive programme of in vitro and in vivo studies. Under the same conditions other quinolones induced effects.</p><p>At high concentrations, Moxifloxacin is an inhibitor of the rapid component of the delayed rectifier potassium current of the heart and may thus cause prolongations of the QT interval. Toxicological studies performed in dogs using oral doses of &ge; 90 mg/kg leading to plasma concentrations &ge; 16 mg/l caused QT prolongations, but no arrhythmias. Only after very high cumulative intravenous administration of more than 50fold the human dose (&gt; 300 mg/kg), leading to plasma concentrations of &ge; 200 mg/l (more than 40fold the therapeutic level), reversible, non-fatal ventricular arrhythmias were seen.</p><p>Quinolones are known to cause lesions in the cartilage of the major diarthrodial joints in immature animals. The lowest oral dose of Moxifloxacin causing joint toxicity in juvenile dogs was four times the maximum recommended therapeutic dose of 400 mg (assuming a 50 kg bodyweight) on a mg/kg basis, with plasma concentrations two to three times higher than those at the maximum therapeutic dose.</p><p>Toxicity tests in rats and monkeys (repeated dosing up to six months) revealed no indication regarding an oculotoxic risk. In dogs, high oral doses (&ge; 60 mg/kg) leading to plasma concentrations &ge; 20 mg/l caused changes in the electroretinogram and in isolated cases an atrophy of the retina.</p><p>Reproductive studies performed in rats, rabbits and monkeys indicate that placental transfer of Moxifloxacin occurs. Studies in rats (p.o. and i.v.) and monkeys (p.o.) did not show evidence of teratogenicity or impairment of fertility following administration of Moxifloxacin. A slightly increased incidence of vertebral and rib malformations was observed in foetuses of rabbits but only at a dose (20 mg/kg i.v.) which was associated with severe maternal toxicity. There was an increase in the incidence of abortions in monkeys and rabbits at human therapeutic plasma concentrations. In rats, decreased foetal weights, an increased prenatal loss, a slightly increased duration of pregnancy and an increased spontaneous activity of some male and female offspring was observed at doses which were 63 times the maximum recommended dose on a mg/kg basis with plasma concentrations in the range of the human therapeutic dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>q&nbsp; Microcrystalline Cellulose 100 Micrometer</p><p>q&nbsp; Mannitol Spray Dried</p><p>q&nbsp; Sodium Starch Glycolate type A</p><p>q&nbsp; Colloidal Anhydrous Silica</p><p>q&nbsp; Magnesium Stearate</p><p>q&nbsp; Opadry II 33G24737 Pink</p><p>q&nbsp; Purified Water</p><p>q&nbsp; White Beeswax</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not applicable.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                                   3 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>q&nbsp; Boxes of 5 blistered tablets of AVORES 400.</p><p>q&nbsp; Boxes of 7 blistered tablets of AVORES 400.</p><p>q&nbsp; Boxes of 336 blistered tablets of AVORES 400.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No special requirements.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any unused product or waste material should be disposed of in accordance with local requirements.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Jordanian Pharmaceutical Manufacturing Co. Ltd.
PO Box 151
Um Al-Amad 16197
Jordan

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>